- Home
- FORA vs TLSA Comparison
FORA vs TLSA Comparison
Compare FORA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | TLSA |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 182.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | FORA | TLSA |
|---|---|---|
| Price | $2.08 | $1.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.1K | ★ 414.9K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,106,911.00 | N/A |
| Revenue This Year | $47.82 | N/A |
| Revenue Next Year | $10.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.47 | N/A |
| 52 Week Low | $1.64 | $0.63 |
| 52 Week High | $4.03 | $2.60 |
Technical Indicators
Market Signals| Indicator | FORA | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 44.78 |
| Support Level | $2.04 | $1.45 |
| Resistance Level | $2.18 | $1.62 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 40.00 | 49.04 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.